Hepatic veno-occlusive disease (VOD) is a common and serious regimen-related toxicity after hematopoietic stem cell transplantation (HSCT). There is no safe and proven therapy for established VOD, and focus has been on its prevention. Previous studies have shown that a continuous infusion of unfractionated heparin or ursodiol may reduce the incidence of VOD. In order to compare the efficacy of heparin plus ursodiol with that of heparin alone, we conducted a prospective, randomized study involving 165 consecutive patients who underwent HSCT for a variety of disorders. Eighty-two patients were assigned to receive heparin plus ursodiol, and 83 were assigned to receive heparin alone. Thirteen and 16 patients were diagnosed as having VOD in the heparin plus ursodiol group and the heparin alone group, respectively (15.9% vs 19.3%; P ‫؍‬ 0.348). Eighty-nine percent of the heparin plus ursodiol group and 89.2% of the heparin alone group were surviving at day 100 post-HSCT (P ‫؍‬ 0.298). The only independent variable associated with an increased risk of VOD was an allogeneic type of HSCT (P ‫؍‬ 0.018). In conclusion, this study shows that there is no difference in efficacy between heparin plus ursodiol and heparin alone for the prevention of hepatic VOD. stem cell transplantation (HSCT), has been reported to occur in 10% to 50% of transplanted patients, with a mortality rate of up to 50% in all affected patients.
stem cell transplantation (HSCT), has been reported to occur in 10% to 50% of transplanted patients, with a mortality rate of up to 50% in all affected patients. [1] [2] [3] [4] The most prominent site of liver damage after cytoreductive therapy is the terminal hepatic venule. 5, 6 In addition to causing vascular changes, cytoreductive therapy may result in necrosis of hepatocytes, engorgement of sinusoids with hepatocytes and red blood cells, and perivenular fibrosis. 3 VOD development after transplantation depends on a variety of risk factors, including a history of liver disease or viral hepatitis, elevated liver enzyme levels before HSCT, primary disease, vancomycin use in the early transplant period, conditioning regimen, patient age, presence of acute graft-versus-host disease (GVHD), type of GVHD prophylaxis, type of transplant, transplant from an HLAmismatched or unrelated donor, and abdominal irradiation. [1] [2] [3] [7] [8] [9] [10] Risk factors for VOD are well established, but the biology of the condition remains poorly understood. No safe and proven therapy for established VOD has been developed and no effective means of prevention has been firmly established. A better understanding of the pathogenesis of VOD will lead to more effective prevention and treatment.
Based on the pathogenesis of VOD in which deposition of coagulation factors within the terminal hepatic venules resulting from endothelial injury was the key event, a continuous infusion of low-dose heparin was given for the prevention of VOD 11 to 161 patients undergoing HSCT. The prophylactic use of heparin was very effective in preventing VOD and did not cause additional bleeding.
Ursodiol (ursodeoxycholic acid; UDCA) is a naturally occurring hydrophilic bile salt that has shown efficacy in the treatment of some hepatic disorders. 12, 13 Recently, prophylactic use of ursodiol has been reported to be effective in decreasing the incidence of VOD without causing major adverse effects. [14] [15] [16] We performed a randomized prospective study to determine whether heparin plus ursodiol decrease the incidence of hepatic VOD and increase the 100-day survival rate after HSCT, compared to heparin alone.
Patients and methods

Patients
Between February 1996 and January 2001, 165 adult patients undergoing either allogeneic or autologous HSCT at Samsung Medical Center were recruited for this study. Patients were excluded from the study if they had had lifethreatening gastrointestinal (GI) or central nervous system (CNS) bleeding within a 2 months period immediately prior to HSCT. Also excluded were patients who had prior allergic reactions to either heparin or ursodiol. Informed consent was obtained from each individual before enrollment. This study protocol was reviewed and approved by the Samsung Medical Center Institutional Review Board. All patients were nursed in a single isolation room with laminar air filter.
Study design
Patients were assigned to receive either heparin plus ursodiol or heparin alone with random permuted block design. All randomized patients started to receive heparin plus ursodiol or heparin alone 12 to 24 h prior to the initiation of their myeloablative regimen. Heparin 5 U/kg/h was administered intravenously without a loading dose and the activated partial thromboplastin time (aPTT) was checked 4 h after the start of the heparin infusion. 11, 17 The aPTT was then monitored daily to be 50 s or less. If the aPTT was longer than 50 s, the dose was adjusted downwards by 50 U/day until the aPTT was 50 s or less. The dose of heparin did not escalate based on aPTT. The daily dose of ursodiol was 600 mg, [14] [15] [16] 300 mg every 12 h by mouth. Heparin and ursodiol continued until day ϩ30 after HSCT or until the day of discharge with a minimum treatment of 15 days post HSCT. Heparin was discontinued for any severe bleeding episode defined as CNS bleeding, bleeding requiring the use of vasopressor agents for more than 1 h, bleeding resulting in a drop in hemoglobin of more than 2 g/dl in a 12 h time period.
Clinical monitoring
All patients enrolled in this study were examined and their weights were recorded on a daily basis. Patients were evaluated for the presence or absence of unexplained weight gain, hepatomegaly, right upper quadrant pain and ascites, or for toxicities known to be related to heparin or ursodiol. Ultrasonography with a Doppler test was performed to evaluate hepatomegaly and ascites at the time of development of suspected or clinically established VOD.
Laboratory tests to be monitored included daily complete blood count and liver function tests (AST, ALT, alkaline phosphatase, bilirubin) as well as prothrombin time (PT) and aPTT. There were additional liver function tests (GGT, LDH, direct bilirubin, fibrinogen) performed weekly.
Hepatic VOD evaluation
Hepatic VOD was diagnosed when at least two of the following occurred concomitantly prior to day ϩ20 after HSCT: jaundice (bilirubin level 2.0 mg/dl or higher), hepatomegaly and/or right upper quadrant pain, and fluid accumulation evidenced by ascites or unexplained weight gain (2% or more above baseline weight). 1 The severity of VOD was defined based on clinical outcomes. 1 Patients who met the criteria for VOD, but whose illness was selflimited without treatment were considered to have mild VOD. Those whose VOD resolved with treatment, such as diuretics for fluid retention or narcotic analgesics for painful hepatomegaly, had moderate VOD. Those who died of VOD or whose VOD did not resolve by day ϩ100 post HSCT were considered to have severe VOD.
Drug formulation, availability and preparation
Heparin sodium was available commercially through Choong Wae Pharmaceutical Company (Seoul, Korea). It was supplied as a buffered, sterile nonpyrogenic solution standardized for anticoagulant activity. Twenty-five thousand units of heparin were mixed in 250 ml of D5W to form a concentration of 100 units per ml.
Ursodiol (ursodeoxycholic acid) was commercially available through Daewoong Pharmaceutical Company (Seoul, Korea). It was supplied in a 100 mg tablet. Ursodiol was classified as a gallstone-solubilizing agent suppressing hepatic synthesis and secretion of cholesterol and also inhibiting intestinal absorption of cholesterol.
Statistical analysis
Two important outcome measures in this study were the incidence of VOD and survival at day ϩ100 post HSCT. Randomization was performed with random permuted block design. Categorical variables were compared using the chi-square test or Fisher's exact test, and continuous variables were compared using the Mann-Whitney test. Survival proportions at day ϩ100 post HSCT between the two groups were compared using the chi-square test. A multivariate analysis was performed to determine the risk factors for the development of VOD by logistic regression model. A P value Ͻ0.05 was considered significant. All analyses were done using SPSS 10.0.
The incidence of VOD was 32.5% in patients receiving heparin alone from the preliminary data of our hospital. Therefore, we were hoping to decrease the incidence down to 16.0% in patients receiving heparin plus ursodiol. Assuming a significance level of 0.05 and a power of 0.8, we needed 2 ϫ 83 ϭ 166 patients.
Results
Patient characteristics
One hundred and sixty-five patients were recruited for the study. Since all of them were qualified for the study, according to the random permuted block design, 82 patients were assigned to the heparin plus ursodiol group, and 83 to the heparin alone group. Seventeen patients (eight from the heparin plus ursodiol group and nine from the heparin alone group) discontinued receiving heparin for VOD prophylaxis before day ϩ15 post HSCT due to bleeding, or sustained prolongation of their aPTT above 50 s without heparin. For intent-to-treat analysis, all 165 patients were followed-up with no regard to heparin discontinuation. Detailed clinical characteristics of these patients are summarized in Table 1 . Pre-transplant characteristics of the two groups were essentially similar with respect to age, sex, primary disease, type of transplant and myeloablative regimen. Also, no significant differences were detected between the two groups in complete blood count, pretreatment liver function tests, history of liver dysfunction or risk factors for VOD. Most of the autologous transplants were performed for solid tumors, multiple myeloma, lymphomas and some of the acute leukemias, while allogeneic transplants were performed for many of the acute leukemias, chronic myeloid leukemia, aplastic anemia, myelodysplastic syndromes and a few other disorders.
Incidence and clinical features of VOD
Twenty-nine of the 165 patients (17.6%) developed VOD. In some cases, clinical manifestations of VOD developed before marrow infusion. The incidence of VOD in the heparin plus ursodiol group was not significantly different from that in the heparin alone group (P ϭ 0.348); VOD was diagnosed in 15.9% (13 of 82 patients) of the heparin plus ursodiol group and 19.3% (16 of 83 patients) of the heparin The dose of TBI was in the range of 1200 to 1500 cGy. The conditioning regimens with TBI were as follows: VP-16 ϩ cytoxan ϩ TBI (29), cytoxan ϩ TBI (14), TBI ϩ VP-16 ϩ Ara-C ϩ cytoxan ϩ methylprednisolone (5), thiotepa ϩ TBI (3), Ara-C ϩ cytoxan ϩ TBI ϩ methylprednisolone (3), melphalan ϩ TBI (2), fludarabine ϩ TBI (2). d Only busulfan ϩ cytoxan (29).
e Others: cytoxan ϩ thiotepa ϩ carboplatin (20) , melphalan alone (15), cytoxan ϩ ATG (14), BCNU ϩ VP-16 ϩ Ara-C ϩ melphalan (11), thiotepa ϩ melphalan (10), thiotepa ϩ carboplatin (3), carboplatin ϩ melphalan (3), VP-16 ϩ cytoxan (2). AML ϭ acute myeloid leukemia; ALL ϭ acute lymphoid leukemia; CML ϭ chronic myeloid leukemia; TBI ϭ total body irradiation.
Bone Marrow Transplantation alone group (Table 2 and Figure 1 ). Table 2 describes the treatment outcomes of all 165 enrolled patients from the first day of prophylactic VOD therapy to post-HSCT day ϩ20. According to previously defined clinical criteria, severe VOD occurred in seven patients with a similar incidence between the two groups, two patients from the heparin plus ursodiol group and five patients from the heparin alone group (P ϭ 0.321). There were no statistically significant differences between the two groups in terms of VOD onset, mean values of laboratory tests such as maximum total bilirubin, maximum PT and maximum aPTT ( Table 2 , P Ͼ0.30). Table 3 describes the clinical features of the 29 patients with clinical VOD from the first day of prophylactic VOD therapy to post-HSCT day ϩ20. VOD began on the median day of post-HSCT day ϩ11 with a range of day ϩ1 to day 15.9% 2.4% Figure 1 The incidence of VOD after HSCT was 17.6%. There was no statistically significant difference in VOD incidence between the heparin plus ursodiol group and the heparin alone group (P a ϭ 0.348). Severe VOD developed in seven patients with no significant difference between the two groups (P b ϭ 0.321). P value calculated by a chi-square test or b Fisher's exact test. H ϭ heparin alone group; HU ϭ heparin plus ursodiol group; VOD ϭ veno-occlusive disease; HSCT ϭ hematopoietic stem cell transplantation.
Bone Marrow Transplantation ϩ20. Hepatomegaly, which was confirmed on ultrasonography by a Doppler test, was reported in 58.6% of these patients. Ascites, which is one of the manifestations of fluid accumulation in VOD, developed in 69.0%. The mean of the maximum unexplained weight gain above the baseline weight, which is another sign of fluid accumulation in VOD, was 12.2%. As far as the laboratory tests were concerned, 82.8% demonstrated either a prolonged PT above 1.5 INR or a prolonged aPTT above 50 s. The mean values of the maximum PT and aPTT were 2.06 INR and 60.4 s, respectively; the mean of the maximum total bilirubin was 9.5 mg/dl. Due to serious bleeding or sustained prolongation of aPTT, heparin administration should have been discontinued before day ϩ15 post HSCT in 41.4% of the total VOD patients.
There were considerable overlaps in the ranges of maximum total bilirubin, maximum PT, maximum aPTT, and weight gain between the two subgroups, divided by VOD severity, non-severe or severe VOD. The non-severe VOD subgroup had 22 patients with mild or moderate clinical VOD, while the severe VOD subgroup had seven with severe clinical VOD. The clinical features of each subgroup, from the first day of prophylactic VOD therapy until post-HSCT day ϩ20, are compared in Table 4 . Firstly, VOD onset was considerably delayed in the non-severe VOD subgroup as compared with the severe VOD subgroup (13.5 days vs 6.0 days; P ϭ 0.024). A significantly higher mean value of maximum total bilirubin was observed in patients with severe VOD (23.5 mg/dl in the severe VOD subgroup and 5.0 mg/dl in the non-severe VOD subgroup; P ϭ 0.001). The mean values of maximum PT and aPTT were significantly prolonged in the severe VOD subgroup (P ϭ 0.001 and 0.031, respectively). Ascites was more frequently observed in the severe subgroup (P ϭ 0.05). There was a trend in favor of the nonsevere VOD subgroup with regard to discontinuation of heparin before day ϩ15 (31.8% vs 71.4%; P ϭ 0.08). Other features, including prolonged PT or aPTT, hepatomegaly and the mean of the maximum weight gain, were not significantly different between the two subgroups (P Ͼ 0.10).
Risk factor analysis
Results of the risk factor analysis for VOD development are shown in Table 5 . Multivariate analysis with a logistic regression model revealed that the only significant risk factor for the development of VOD, regardless of either VOD prophylaxes, was an allogeneic type of HSCT (allogeneic: autologous ϭ 26/81:3/84, P ϭ 0.018). Other previously known factors, such as donor type, primary disease, conditioning regimen containing TBI or busulfan, elevated transaminase, viral hepatitis B, vancomycin use and previous irradiation to abdomen, did not affect VOD development (P Ͼ 0.20).
Incidence of VOD in patients undergoing allogeneic HSCT
The overall incidence of VOD in all patients undergoing allogeneic HSCT was 32.1% (26/81), and the incidence of severe VOD was 8.6% (7/81). The incidence of VOD or severe VOD in patients undergoing allogeneic HSCT was not significantly different between the heparin plus ursodiol group and the heparin alone group; 13 patients developed VOD in each group (13/38 vs 13/43, P ϭ 0.702), and two and five patients developed severe VOD in the heparin plus ursodiol group and the heparin alone group, respectively (2/38 vs 5/43, P ϭ 0.189).
Post-transplant 100-day survival
At day ϩ100 post HSCT, 89.0% (73 of the 82 patients) in the heparin plus ursodiol group and 89.2% (74 of the 83 patients) in the heparin alone group survived (Figure 2 , P ϭ 0.298). All seven patients with severe VOD died of hepatic failure resulting from hepatic VOD. The use of ursodiol in addition to heparin failed to improve the 100-day survival rate.
Toxicity
Although 26 patients experienced various grades of bleeding during the course of VOD prophylaxis, only one patient died of severe bleeding. Some of the bleeding episodes were directly related to heparin use, but others were only aggravated by heparin use. Besides bleeding, there were no other side-effects clearly ascribable to the use of heparin or ursodiol.
Discussion
There is a wide intercenter variation in terms of incidence and risk factors for hepatic VOD. This disparity may be due to differences in the intensity of conditioning, patient characteristics, and diagnostic criteria of VOD. The Seattle and Baltimore groups 1, 3 have established the clinical criteria for the diagnosis of VOD. Unfavorable prognostic factors include renal failure, hepatic encephalopathy and profound jaundice.
The overall incidence of VOD was very different between the two studies; 5.3% and 53.5%, respectively. However, severe VOD developed with similar rates among VOD patients in each study, 27.6% and 28.4% of all VOD.
1,2 In our study, hepatic VOD developed in 29 out of 165 enrolled patients (17.6%) and severe VOD developed in seven out of 29 VOD patients (24.1%), with a similar incidence between the heparin plus ursodiol group and the heparin alone group (P ϭ 0.348 and 0.321, respectively).
The risk factors associated with VOD development
Bone Marrow Transplantation differed among the studies. We analyzed a variety of previously known factors for risk of VOD: type of transplantation (allogeneic vs autologous), donor type in allogeneic transplantation (matched sibling vs alternative), primary disease, conditioning regimen with total body irradiation (TBI) or busulfan, elevated transaminase values before transplantation, a history of viral hepatitis B, vancomycin administration during conditioning therapy, and previous irradiation to the abdomen. [1] [2] [3] [4] In our study, only an allogeneic type of HSCT was significantly associated with risk of VOD (Table 5) .
Endothelial injury of sinusoids and hepatic venules related to the conditioning therapy has been known to be the initiating event in hepatic VOD. 18 This phenomenon results in a local hypercoagulable state due to increased tissue factor production, with activation of the coagulation cascade and downregulation of the natural anticoagulant system via thrombomodulin and release of von Willebrand factor. Several groups evaluated the levels of coagulation proteins and naturally occurring anticoagulants before and after conditioning therapy. In general, preconditioning levels of protein C, factor VII, antithrombin III (AT III) and plasminogen were lower in patients who developed VOD compared with those who did not; the levels of protein C, protein S, AT III, factor VII and factor X decreased after the transplantation. None of these parameters, however, consistently predicted the patients at risk of developing VOD. We assessed the PT and aPTT in patients with VOD to determine whether PT or aPTT were associated with the severity of VOD. PT and aPTT could be used as comprehensive laboratory tests to indicate any abnormalities of the coagulation factors involved in the pathogenesis of hepatic VOD. Moreover, PT and aPTT could reflect the degree of hepatic dysfunction, directly associated with the prognosis of hepatic VOD. The mean values of the maximum PT and aPTT were significantly different between the non-severe VOD group and severe VOD group (P ϭ 0.001 and 0.031, respectively). However, the percentage of patients with a prolonged PT Ͼ1.5 INR or aPTT Ͼ50 s was not significantly different between the two groups (P ϭ 0.222). In addition, the difference in the percentage of patients that discontinued heparin before post-HSCT day ϩ15 due to prolonged aPTT or bleeding was not statistically significant between the two groups but the severe VOD group tended to discontinue heparin treatment after the transplantation (Table 4 , P ϭ 0.08).
The common differential diagnoses of hepatic VOD include hyperacute hepatic GVHD, adverse effect of drugs, viral hepatitis, fungal infection, septicemia, and so on. To confirm the diagnosis of hepatic VOD, liver histology is required; however, liver biopsy is neither feasible nor available frequently. The efficiency of Doppler ultrasound examination is controversial in the diagnosis of VOD. The high predictive value (88.5%) of the clinical diagnosis of VOD along with difficulty in histologic confirmation has authorized physicians to make the diagnosis based on clinical features alone. 4 Among the clinical features of hepatic VOD, VOD onset, ascites, mean values of maximum total bilirubin, PT and aPTT were significantly different between the non-severe and severe VOD groups in this study (Table 4) .
Although the majority of patients with non-severe VOD recover completely, those belonging to the severe category are apt to die of multiorgan failure. Therefore, in order to define the severe category of VOD more precisely based on laboratory data besides the clinical features relevant to hepatic VOD, it is necessary to investigate whether each laboratory item pertinent to the pathogenesis of VOD affects the prognosis of VOD. Bearman et al 19 proposed that the total serum bilirubin and weight gained within 1 to 2 weeks of transplantation could predict the prognosis of VOD. In our study, the maximum total bilirubin was significantly higher in the severe VOD group than in the non-severe group, in accordance with the Seattle group 1 (Table 4 ). In addition to the total serum bilirubin, the mean values of the maximum PT and aPTT were significantly prolonged with the severe type of VOD (P ϭ 0.001 and 0.031, respectively).
Based on our results regarding PT and aPTT in patients with VOD, it is worth investigating whether PT or aPTT could be used as prognostic factors to predict the prognosis of VOD as reliably as the total serum bilirubin or weight. Heparin, 2, 11, 17, 20 low molecular weight heparin, 21 ursodiol, [14] [15] [16] prostaglandin E 1 (PEG 1 ), 22, 23 and pentoxifylline [24] [25] [26] have been tried without consistent effectiveness for the prevention of hepatic VOD after HSCT. In a randomized double-blind placebo-controlled trial, 15 ursodiol has been shown to be effective in preventing hepatic VOD after allogeneic bone marrow transplantation. In our study, however, the addition of ursodiol to heparin failed to provide any benefit over heparin alone (Figures 1 and 2) . Even in the patients undergoing allogeneic HSCT, which was recognized as a risk factor for VOD in this study, ursodiol did not help decrease the incidence of VOD.
In summary, our randomized prospective study demonstrated that there was no difference in the efficacy between heparin plus ursodiol and heparin alone for the prevention of hepatic VOD. In other words, the addition of ursodiol to heparin failed to decrease the incidence of hepatic VOD or to improve the 100-day survival rate after HSCT. The only independent risk factor for hepatic VOD following HSCT was an allogeneic type of transplant.
